Carmen Lome-Maldonado

Carmen Lome-Maldonado

Auto-generated profile, based on publicly available information

Carmen Lome-Maldonado

Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Thrombosis Research
Verified
Journal Article
Closed access
GCGabriela Cesarman Cesarman-Maus
Gabriela Cesarman Cesarman-Maus
EBEsteban Braggio
Esteban Braggio
CLCarmen Lome-Maldonado
Carmen Lome-Maldonado
AMAna Lilia Morales-Leyte
Ana Lilia Morales-Leyte
RFRafael Fonseca
Rafael Fonseca

23 February 2020 in International Journal of STD & AIDS
Verified
Journal Article
Open access
PDF file
PVPatricia Volkow
Patricia Volkow
CLC Lome-Maldonado
C Lome-Maldonado
HQH Quintero-Buenrostro
H Quintero-Buenrostro
BIBEDA DANIELA ISLAS-MUÑOZ
BEDA DANIELA ISLAS-MUÑOZ
PJPatricia Cornejo Juarez
Patricia Cornejo Juarez
The aim of this study is to describe the clinical characteristics and outcome of multicentric Castleman disease (MCD) in HIV-infected patients at an oncological referral center in Mexico. Clinical records at the HIV-AIDS clinic of all patients diagnosed with MCD from 1994 to 2018 were reviewed. There were 19 patients, mean age was 31.3 ± 8.4 years, and 17 (89.5%) were males. Fifteen patients (79%) had also Kaposi sarcoma (KS). Main clinical characteristics were multiple lymphadenopathy (95%), systemic symptoms (63%), and hepatosplenomegaly (50%). Computed tomography scan and 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography showed multiple lymphadenopathy, inversion of the liver:spleen uptake ratio, with an increase in SUVmax (5.7). The histopathology report described plasma cells in 58%, mixed type in 26%, and hyaline vascular in 16%. Eleven patients (57.9%) received different chemotherapy regimens. Seven patients died (36.8%): four related to MCD progression or chemotherapy complications, median survival was eight months. For those patients who survived, median, follow-up was 28 months (p < 0.001). The incidence of MCD in people living with HIV is probably underestimated. In patients with lymphadenopathy, B symptoms, deranged inflammatory markers, and/or disseminated KS, a biopsy of an enlarged lymph node is warranted, and the histology should be reviewed by an experienced pathologist.

27 June 2023 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
NPNatalia Papaleo
Natalia Papaleo
Fina ClimentFina Climent
Fina Climent
GTGustavo Tapia
Gustavo Tapia
LLLuis Luizaga
Luis Luizaga
JAJuan Azcarate
Juan Azcarate
Luis ColomoLuis Colomo
Luis Colomo
Aggressive large B-cell lymphomas (aLBCL) include a heterogeneous group of lymphomas with diverse biological features. One of the approaches to the diagnosis of aLBCL is based on the identification of MYC rearrangements (MYC-R), in addition to BCL2 and BCL6 rearrangements by genetic techniques, mainly fluorescent in situ hybridization (FISH). Because of the low incidence of MYC-R, the identification of useful immunohistochemistry markers to select cases for MYC FISH testing may be useful in daily practice. In a previous work, we identified a strong association between the profile CD10 positive/LMO2 negative expression and the presence of MYC-R in aLBCL and obtained good intralaboratory reproducibility. In this study, we wanted to evaluate external reproducibility. To evaluate whether LMO2 can be a reproducible marker between observers 50 aLBCL cases were circulated among 7 hematopathologists of 5 hospitals. Fleiss’ kappa index for LMO2 and MYC were 0.87 and 0.70, respectively, indicating high agreement between observers. In addition, during 2021–2022, the enrolled centers included LMO2 in their diagnostic panels to evaluate prospectively the utility of the marker, and 213 cases were analyzed. Comparing LMO2 with MYC, the group of CD10 positive cases showed higher specificity (86% vs 79%), positive predictive value (66% vs 58%), likelihood positive value (5.47 vs 3.78), and accuracy (83% vs 79%), whereas the negative predictive values remained similar (90% vs 91%). These findings place LMO2 as a useful and reproducible marker to screen MYC-R in aLBCL.

22 October 2024 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
NPNatalia Papaleo
Natalia Papaleo
AMAndrea Molina-Alvarez
Andrea Molina-Alvarez
GTGustavo Tapia
Gustavo Tapia
RORicard Onieva
Ricard Onieva
MSMarta Salido
Marta Salido
Luis ColomoLuis Colomo
Luis Colomo